The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Aclaris Therapeutics Issued US Patents Covering JAK Inhibitors for Treating Hair Loss Disorders

07-Sep-2017 | Source : Aclaris Therapeutics | Visits : 5777
MALVERN, Pa. - Aclaris Therapeutics Inc. announced in a press release that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 9,737,469 and US Patent No. 9,730,877, which are directed to methods related to the use and administration of certain janus kinase (JAK) inhibitors for treating hair loss disorders. 

US Patent No. 9,730,877 covers the use of various JAK inhibitors, including tofacitinib, baricitinib, ruxolitinib and decernotinib, to treat androgenetic alopecia, also known as male/female pattern hair loss. Experienced by 70% of men and 40% of women at some point in their lives, androgenetic alopecia is a genetic disorder and the most common cause of hair loss. The ‘877 Patent contains 22 claims and expires in November 2031.

US Patent No. 9,737,469 covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.  Additional issued claims pertain to methods of using baricitinib to treat particular phenotypes of alopecia areata, as well as to treat other hair loss disorders. The ‘469 Patent contains 10 claims and expires in November 2031. 

These newly allowed patents are owned by The Trustees of Columbia University in the City of New York and exclusively licensed to Aclaris, and are the latest US patents to issue in connection with Aclaris' JAK drug development program for hair loss disorders.

“We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia.  These new issuances continue to expand the breadth and depth of our JAK inhibitor intellectual property portfolio covering methods of use for certain JAK inhibitors for the treatment of hair loss disorders. The issuance of these patents is another successful step in the development of a robust patent portfolio relating to JAK inhibition and hair loss,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

Aclaris has exclusively licensed several patents and patent applications involving novel selective JAK 1/3 inhibitors, including a patent portfolio from Rigel Pharmaceuticals, Inc. that covers Aclaris’ product candidates ATI-50001 and ATI-50002, which are oral and topical formulations, respectively, also being developed as potential treatments for alopecia areata.  Additionally, Aclaris has exclusively licensed a patent portfolio from Columbia University directed to methods of using JAK inhibitors for the treatment of alopecia areata, androgenetic alopecia, and other dermatological conditions.  This portfolio includes the recently issued U.S. patents discussed above, as well as an issued U.S. patent directed to methods of treating alopecia areata, androgenetic alopecia and other hair loss disorders by administering ruxolitinib and issued patent claims in Japandirected to pharmaceutical compositions comprising ruxolitinib, baricitinib or other JAK inhibitors for use in treating alopecia areata, androgenetic alopecia and other hair loss disorders.

Related Articles